NEWS

We’ve been busy. Catch up on the latest news, updates and happenings at Synthekine.

Press ReleasesPosters and Publications

Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK-012 in First-Line Non-Squamous NSCLC in Oral Presentation at AACR 2026

/in , /by

April 21, 2026

Read more

Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK 012 in First Line Nonsquamous NSCLC with Features of Immunotherapy Resistance

/in , /by

March 17, 2026

Read more

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

/in , /by

February 26, 2026

Read more

First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

/in , /by

November 13, 2025

Read more

Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

/in , /by

November 7, 2025

Read more

Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting

/in , /by

October 30, 2025

Read more

Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting

/in , /by

December 9, 2024

Read more

Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024

/in , /by

November 15, 2024

Read more

Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

/in , /by

November 8, 2024

Read more

Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion

/in , /by

September 4, 2024

Read more

Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion

/in , /by

March 26, 2024

Read more

Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window

/in , /by

November 3, 2023

Read more

Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies

/in , /by

July 27, 2023

Read more

Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting

/in , /by

April 7, 2022

Read more

Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform

/in , /by

June 10, 2021

Read more

Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities

/in , /by

April 10, 2021

Read more

Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T

/in , /by

December 7, 2020

Read more

Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases

/in , /by

September 17, 2020

Read more

IL-2

2026 – AACR

2025 – SITC

2025 – SITC

2024 – SITC

2024 – ICIS

2024 – The Promise of Interleukin-2 Therapy

2024 – KCRS

2024 – AACR

2023 – PEGS Summit

2023 – AACR

2022 – AACR

2021 – AACR

Orthogonal IL-2

2025 – Keystone Symposia

2025 – ASGCT

2024 – ASH

2024 – ACR

2024 – ICIS

2024 – PEGS Summit

2024 – AACR

2023 – PEGS Europe

2023 – AACR

2023 – Keystone Symposia

2022 – AACR

2022 – AACR

2021 – Science Translational Medicine 

2021 – SITC Pre-Conference Program 

2021 – The Journal of Clinical Investigation 

2021 – AACR 

2020 – ASH 

2020 – AACR 

2018 – Science 

IL-12

2024 – SITC

2024 – SITC

2023 – SITC

2023 – AACR

2021 – Cell

IL-10

2023 – ICIS

2021 – Science

IL-22

2025 – Obesity Week

2025 – ADA

2021 – Immunity

IL-18

2024 – ICIS

2024 – PEGS Summit

IFN-gamma

2019 – Nature  

Surrogate Cytokine Agonists

2025 – Antibodies

2023 – PEGS Summit

2022 – Cytokines

2022 – AACR

2022 – AACR

Facile discovery of surrogate cytokine agonists

2022 – Cell

2017 – eLife

2015 – Cell